Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Blood Based Biomarkers Market?

The market size of blood-based biomarkers has seen considerable growth in the past few years. The size of the market, which was $23.13 billion in 2024, is projected to increase to $26.06 billion in 2025, showing a compound annual growth rate (CAGR) of 12.6%. The acceleration during the historic period is linked to numerous factors such as the increased incidence of cancer worldwide, the rising popularity of personalized medicine, greater investment in biomarker research, growth in clinical trials utilizing biomarkers, and an increase in approvals for companion diagnostics.

What Growth Rate Is Forecasted for the Blood Based Biomarkers Market by 2029?

In the coming years, the blood-based biomarkers market is projected to experience substantial expansion, with the market size predicted to increase to $41.55 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. This progression in the projected phase is linked to the development in AI and machine learning applied to biomarker analysis, increased need for early detection of diseases, the emergence of telemedicine and remote diagnosis, an uptick in chronic disease cases, and heightened health consciousness among consumers. Key trends expected in this projection period are the emergence of AI-aided biomarker discovery, advancements in liquid biopsy, the combination of multi-omics, the introduction of point-of-care (POC) testing devices, and innovations in next-generation sequencing (NGS).

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp

Which Key Companies Are Shaping the Future of the Blood Based Biomarkers Market?

Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG

Which Factors Are Driving Demand in the Blood Based Biomarkers Industry?

The escalation in cardiovascular disease incidents is anticipated to boost the expansion of the blood-based biomarkers market in the future. Cardiovascular afflictions pertain to a collection of issues that impact the heart and blood vessels, incorporating ailments such as coronary artery disease, heart failure, and stroke. Factors contributing to an increase in cardiovascular disease include unhealthy diets and escalating rates of obesity. Blood-based biomarkers assist in the diagnosis and tracking of cardiovascular diseases, offering insights into the progression of the disease, risk evaluation, and the response to treatment via substances that can be measured in the blood. For example, in September 2024, the National Center for Biotechnology Information, a government agency in the US, reported a worldwide health research initiative. Predictions pointed to a 90% increase in the prevalence of cardiovascular disease between 2025 and 2050, with the count of expected deaths due to cardiovascular conditions reaching 35.6 million by 2050. Consequently, the escalating incidents of cardiovascular diseases are fuelling the growth of blood-based biomarkers.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp

How Is the Blood Based Biomarkers Market Segmented by Several Divisions?

The blood based biomarkers market covered in this report is segmented –

1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers

2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies

3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications

4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users

Subsegments:

1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions

2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins

3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels

4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells

5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity

What are the Emerging Market Trends Driving the Growth of the Blood Based Biomarkers Industry?

Leading companies in the blood-based biomarkers market are prioritizing technological progression such as sophisticated blood biomarker tests to assist doctors in diagnosing Alzheimer’s disease. A blood biomarker test, with high-accuracy, is a diagnostic instrument that employs distinct biomarkers in the blood to accurately and reliably identify diseases or track health conditions. For example, in October 2023, Quanterix, an American life sciences firm, came out with a high-accuracy blood biomarker test named LucentAD p-Tau 217. This test is designed to help physicians diagnose Alzheimer’s disease (AD) in adults who have cognitive impairment. The test gauges phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker that is closely tied to AD pathology, notably the accumulation of amyloid in the brain. The LucentAD p-Tau 217 test boasts an accuracy rate of over 90%, satisfying stringent diagnostic standards, and is meant to supplement other diagnostic tools instead of being used as an independent test.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report

Which Regions Are Driving Growth in the Blood Based Biomarkers Market?

North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24176&type=smp

This Report Delivers Insight On:

1. How big is the blood based biomarkers market, and how is it changing globally?

2. Who are the major companies in the blood based biomarkers market, and how are they performing?

3. What are the key opportunities and risks in the blood based biomarkers market right now?

4. Which products or customer segments are growing the most in the blood based biomarkers market?

5. What factors are helping or slowing down the growth of the blood based biomarkers market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model